- Home
- GRRRW vs ICUCW Comparison
GRRRW vs ICUCW Comparison
Compare GRRRW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRRW | ICUCW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United Kingdom | United States |
| Employees | 143 | 18 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRRRW | ICUCW |
|---|---|---|
| Price | $0.25 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 336.7K | N/A |
| Earning Date | 04-04-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $78,940,347.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.04 | ★ N/A |
| Revenue Growth | ★ 424.97 | N/A |
| 52 Week Low | $1.06 | N/A |
| 52 Week High | $1.54 | N/A |
Technical Indicators
Market Signals| Indicator | GRRRW | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 40.41 |
| Support Level | $0.25 | $0.01 |
| Resistance Level | $0.52 | $0.01 |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.07 | 50.00 |
Price Performance
Historical ComparisonAbout GRRRW Gorilla Technology Group Inc. Warrant
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.